Matches in SemOpenAlex for { <https://semopenalex.org/work/W4312563335> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W4312563335 endingPage "40" @default.
- W4312563335 startingPage "40" @default.
- W4312563335 abstract "With more than 10 million deaths per year, cancer is the main cause of mortality in the world. The traditional nonsurgical treatments, chemotherapy and radiotherapy, are associated with high morbidity rates, acting nonspecifically on all cell types, including the healthy ones. This is the reason why, in the past 20 years, novel anticancer biological therapies have emerged. By stimulating the body’s own immune system to fight against cancer cells, interfering with progression and tumor growth, these drugs target the cancerous cells only, the impact on normal tissues being minimal. Biological therapy has thus become an important component of systemic treatment in a large range of tumors. Despite the targeted mechanism, numerous side effects of biological therapy have been described, mainly regarding the digestive system, liver, skin, central nervous and cardiovascular system. There are few studies regarding the ocular side effects of these treatments. The main ocular pathologies associated with biological therapy are dry eye syndrome (1-24%), uveitis (1%) and myasthenia gravis with extraocular muscle involvement. Although rare (1%), ocular side effects can have serious consequences on the quality of life and can influence the patient’s compliance with systemic therapy. Furthermore, we must keep in mind that, as biological therapies become more widely used, the side effects will be more frequently encountered and reported. In Romania, there are no centralized data regarding the ocular side effects determined by cancer treatments in general or by biological therapies in solid tumors in particular, especially since it is a newly introduced therapeutic option in current practice. Based on the relevant data from the specialized literature, we want to highlight the most frequent ocular side effects, establish an ophthalmological follow-up protocol for the cancer patient according to the frequency, but also the time of appearance of eye pathologies, as well as to improve the therapeutic protocol for eye conditions in patients undergoing systemic anticancer treatment in Romania." @default.
- W4312563335 created "2023-01-05" @default.
- W4312563335 creator A5036617690 @default.
- W4312563335 creator A5051338764 @default.
- W4312563335 creator A5067625882 @default.
- W4312563335 date "2022-01-01" @default.
- W4312563335 modified "2023-10-18" @default.
- W4312563335 title "Toxicitatea oculară a terapiilor biologice în tumorile solide" @default.
- W4312563335 cites W1971915780 @default.
- W4312563335 cites W1972524071 @default.
- W4312563335 cites W1982794477 @default.
- W4312563335 cites W2006156545 @default.
- W4312563335 cites W2011452955 @default.
- W4312563335 cites W2041454316 @default.
- W4312563335 cites W2052938321 @default.
- W4312563335 cites W2063175933 @default.
- W4312563335 cites W2067079841 @default.
- W4312563335 cites W2070134980 @default.
- W4312563335 cites W2081033328 @default.
- W4312563335 cites W2109465910 @default.
- W4312563335 cites W2122812204 @default.
- W4312563335 cites W2132168755 @default.
- W4312563335 cites W2141779237 @default.
- W4312563335 cites W2170017292 @default.
- W4312563335 cites W2317657428 @default.
- W4312563335 cites W2324607802 @default.
- W4312563335 cites W2344489622 @default.
- W4312563335 cites W2587959153 @default.
- W4312563335 cites W2606778219 @default.
- W4312563335 cites W3195102101 @default.
- W4312563335 cites W74687677 @default.
- W4312563335 doi "https://doi.org/10.26416/onhe.61.4.2022.7416" @default.
- W4312563335 hasPublicationYear "2022" @default.
- W4312563335 type Work @default.
- W4312563335 citedByCount "0" @default.
- W4312563335 crossrefType "journal-article" @default.
- W4312563335 hasAuthorship W4312563335A5036617690 @default.
- W4312563335 hasAuthorship W4312563335A5051338764 @default.
- W4312563335 hasAuthorship W4312563335A5067625882 @default.
- W4312563335 hasBestOaLocation W43125633351 @default.
- W4312563335 hasConcept C121608353 @default.
- W4312563335 hasConcept C126322002 @default.
- W4312563335 hasConcept C199360897 @default.
- W4312563335 hasConcept C3454156 @default.
- W4312563335 hasConcept C41008148 @default.
- W4312563335 hasConcept C509974204 @default.
- W4312563335 hasConcept C71924100 @default.
- W4312563335 hasConceptScore W4312563335C121608353 @default.
- W4312563335 hasConceptScore W4312563335C126322002 @default.
- W4312563335 hasConceptScore W4312563335C199360897 @default.
- W4312563335 hasConceptScore W4312563335C3454156 @default.
- W4312563335 hasConceptScore W4312563335C41008148 @default.
- W4312563335 hasConceptScore W4312563335C509974204 @default.
- W4312563335 hasConceptScore W4312563335C71924100 @default.
- W4312563335 hasIssue "61" @default.
- W4312563335 hasLocation W43125633351 @default.
- W4312563335 hasOpenAccess W4312563335 @default.
- W4312563335 hasPrimaryLocation W43125633351 @default.
- W4312563335 hasRelatedWork W1175974267 @default.
- W4312563335 hasRelatedWork W1975180830 @default.
- W4312563335 hasRelatedWork W200989379 @default.
- W4312563335 hasRelatedWork W2130548089 @default.
- W4312563335 hasRelatedWork W2384708512 @default.
- W4312563335 hasRelatedWork W2389796598 @default.
- W4312563335 hasRelatedWork W2799994636 @default.
- W4312563335 hasRelatedWork W3111975802 @default.
- W4312563335 hasRelatedWork W4221073380 @default.
- W4312563335 hasRelatedWork W4322772323 @default.
- W4312563335 hasVolume "4" @default.
- W4312563335 isParatext "false" @default.
- W4312563335 isRetracted "false" @default.
- W4312563335 workType "article" @default.